Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

The Journal of investigative dermatology - 1 Jul 2012

Gowrishankar Kavitha, Snoyman Stephanie, Pupo Gulietta M, Becker Therese M, Kefford Richard F, Rizos Helen

Abstract excerpt

Aberrant activation of the BRAF kinase occurs in ∼60% of melanomas, and although BRAF inhibitors have shown significant early clinical success, acquired resistance occurs in most patients. Resistance to chronic BRAF inhibition often involves reactivation of mitogen-activated protein kinase (MAPK) signaling, and the combined targeting of BRAF and its downstream target MAPK/ERK kinase (MEK) may delay or overcome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, ras
Share to Imidazoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mitogen-Activated Protein Kinases

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 22437314
DOI: 10.1038/jid.2012.63

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.PMID 22437314Read ↗

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant CancersSemantic proximity Read ↗

Resistance to BRAF-targeted therapy in melanoma.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.